

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 May 2025 (30.05.2025)



(10) International Publication Number
WO 2025/111547 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) C07D 519/00 (2006.01)
A61P 21/00 (2006.01) A61K 31/4375 (2006.01)
C07D 487/04 (2006.01)

(21) International Application Number:

PCT/US2024/057078

(22) International Filing Date:

22 November 2024 (22.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/601,947 22 November 2023 (22.11.2023) US

(71) Applicant: **RGENTA THERAPEUTICS, INC.** [US/US];
300 Tradecenter, Suite 6600, Woburn, Massachusetts 01801
(US).

(72) Inventors: **YATES, Christopher M.**; c/o RGENTA
THERAPEUTICS, INC., 300 Tradecenter, Suite 6600,
Woburn, Massachusetts 01801 (US). **WAGER, Travis T.**;
c/o RGENTA THERAPEUTICS, INC., 300 Tradecenter,
Suite 6600, Woburn, Massachusetts 01801 (US). **BAR-**
TOLOZZI, Alessandra; c/o RGENTA THERAPEUTICS,
INC., 300 Tradecenter, Suite 6600, Woburn, Massachusetts
01801 (US). **PROUDFOOT, John Robert**; c/o RGEN-
TA THERAPEUTICS, INC., 300 Tradecenter, Suite 6600,
Woburn, Massachusetts 01801 (US). **WYNN, Thomas An-**
drew; c/o RGENTA THERAPEUTICS, INC., 300 Trade-
center, Suite 6600, Woburn, Massachusetts 01801 (US).

(74) Agent: **HALEY, Christopher et al.**; Goodwin Procter LLP,
IP DOCKETING DEPT./ 7TH FL, 100 Northern Avenue,
Boston, Massachusetts 02122 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,


HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: 2,3-DIHYDROPYRROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF



(57) Abstract: The present disclosure relates to compounds of Formula (I) or subformulas thereof: (I) and pharmaceutically acceptable salts thereof, and their uses in treating PMS1 -associated diseases and disorders.



WO 2025/111547 A1